Studies on aspirin keep coming. For decades, studies found that persons taking aspirin frequently have a lowered risk of developing colorectal (colon) cancer, and that they are less likely to die if they do develop colorectal cancer. A recent study confirmed these aspirin findings and looked at what is occurring.
Aspirin appears to boost or activate the immune system, which helps explain its protective effect in colorectal cancer. Clinical trials are going on now to test whether and how aspirin can be part of colorectal cancer treatment.
From Medscape: How Aspirin May Lower Risk for Colorectal Cancer
A 2020 meta-analysis, for instance, found that 325 mg of daily aspirin — the typical dose in a single tablet — conferred a 35% reduced risk of developing CRC, and a highly cited The Lancet study from 2010 found that a low dose of daily aspirin reduced the incidence of colon cancer by 24% and colon cancer deaths by 35% over 20 years.
The evidence surrounding aspirin and CRC is so intriguing that more than 70,000 people are currently participating in more than 2 dozen clinical studies worldwide, putting aspirin through its paces as an intervention in CRC.
But what, exactly, is aspirin doing?
...continue reading "Aspirin and Lower Risk of Colorectal Cancer"